IL83291A0 - Monoclonal antibody against ovarian cancer cells(ovb-3) - Google Patents
Monoclonal antibody against ovarian cancer cells(ovb-3)Info
- Publication number
- IL83291A0 IL83291A0 IL83291A IL8329187A IL83291A0 IL 83291 A0 IL83291 A0 IL 83291A0 IL 83291 A IL83291 A IL 83291A IL 8329187 A IL8329187 A IL 8329187A IL 83291 A0 IL83291 A0 IL 83291A0
- Authority
- IL
- Israel
- Prior art keywords
- ovb
- monoclonal antibody
- cancer cells
- ovarian cancer
- antibody against
- Prior art date
Links
- 206010033128 Ovarian cancer Diseases 0.000 title 1
- 206010061535 Ovarian neoplasm Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/888,960 US4806494A (en) | 1986-07-24 | 1986-07-24 | Monoclonal antibody against ovarian cancer cells (OVB-3) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL83291A0 true IL83291A0 (en) | 1987-12-31 |
Family
ID=25394255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL83291A IL83291A0 (en) | 1986-07-24 | 1987-07-22 | Monoclonal antibody against ovarian cancer cells(ovb-3) |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4806494A (fr) |
| EP (1) | EP0277970A4 (fr) |
| AU (1) | AU7784187A (fr) |
| DK (1) | DK283588A (fr) |
| IL (1) | IL83291A0 (fr) |
| WO (1) | WO1988000703A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1289880C (fr) * | 1985-12-06 | 1991-10-01 | Jeffrey L. Winkelhake | Immunotoxines contre le cancer des ovaires chez les humains et methode d'utilisation |
| US4962188A (en) * | 1985-12-06 | 1990-10-09 | Cetus Corporation | Recombinant ricin toxin A chain conjugates |
| US4956453A (en) * | 1985-12-06 | 1990-09-11 | Cetus Corporation | Anti-human ovarian cancer immunotoxins and methods of use thereof |
| JPH02196799A (ja) * | 1988-04-08 | 1990-08-03 | Agency Of Ind Science & Technol | 抗ヒト癌蛋白複合体 |
| US5858363A (en) * | 1990-07-20 | 1999-01-12 | Pharmacia & Upjohn Ab | Target specific antibody-superantigen conjugates and their preparation |
| DE69122777T2 (de) * | 1990-07-20 | 1997-04-10 | Pharmacia & Upjohn Ab, Stockholm | Zielgerichtete spezifische antikörper-superantigen konjugate und ihre präparation |
| DK0554356T3 (da) * | 1990-10-12 | 1999-06-14 | Us Health | Monoklonalt antistof |
| US5366866A (en) * | 1991-07-25 | 1994-11-22 | Duke University | Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB |
| US5484704A (en) * | 1992-11-12 | 1996-01-16 | Baylor College Of Medicine | Monoclonal antibody for diagnostic use in ovarian cancer |
| US5690935A (en) * | 1995-01-13 | 1997-11-25 | Regents Of The University Of Minnesota | Biotherapy of cancer by targeting TP-3/P80 |
| US7192709B2 (en) * | 2004-03-15 | 2007-03-20 | Digigenomics Co., Ltd. | Methods for identification, assessment, prevention, and therapy of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4664911A (en) * | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
| US4666845A (en) * | 1983-12-16 | 1987-05-19 | Sloan-Kettering Institute | Monoclonal antibodies to ovarian, cervical and uterine human cancers and method of diagnosis |
| US4545985A (en) * | 1984-01-26 | 1985-10-08 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Pseudomonas exotoxin conjugate immunotoxins |
| US4678667A (en) * | 1985-07-02 | 1987-07-07 | 501 Regents of the University of California | Macrocyclic bifunctional chelating agents |
| ATE76583T1 (de) * | 1985-12-06 | 1992-06-15 | Cetus Corp | Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung. |
-
1986
- 1986-07-24 US US06/888,960 patent/US4806494A/en not_active Expired - Fee Related
-
1987
- 1987-07-20 EP EP19870905058 patent/EP0277970A4/fr not_active Withdrawn
- 1987-07-20 AU AU77841/87A patent/AU7784187A/en not_active Abandoned
- 1987-07-20 WO PCT/US1987/001667 patent/WO1988000703A1/fr not_active Ceased
- 1987-07-22 IL IL83291A patent/IL83291A0/xx unknown
-
1988
- 1988-05-24 DK DK283588A patent/DK283588A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0277970A4 (fr) | 1988-10-20 |
| AU7784187A (en) | 1988-02-10 |
| DK283588D0 (da) | 1988-05-24 |
| US4806494A (en) | 1989-02-21 |
| EP0277970A1 (fr) | 1988-08-17 |
| WO1988000703A1 (fr) | 1988-01-28 |
| DK283588A (da) | 1988-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU588542B2 (en) | Immunoassay for breast cancer employing monoclonal antibodies | |
| GB8608068D0 (en) | Monoclonal antibodies | |
| IL83291A0 (en) | Monoclonal antibody against ovarian cancer cells(ovb-3) | |
| GB8624899D0 (en) | Monoclonal antibodies | |
| GB8422650D0 (en) | Monoclonal antibodies | |
| GB8621910D0 (en) | Monoclonal antibodies | |
| EP0267601A3 (en) | Anti-pci monoclonal antibody | |
| GB8715347D0 (en) | Monoclonal antibodies | |
| PT79896A (en) | Monoclonal antibody | |
| GB8616174D0 (en) | Monoclonal antibodies | |
| EP0253646A3 (en) | Anti-human gastric cancer monoclonal antibody | |
| EP0180413A3 (en) | Anti-human cancer monoclonal antibody | |
| GB8422649D0 (en) | Monoclonal antibodies | |
| GB8422651D0 (en) | Monoclonal antibodies | |
| AU618720B2 (en) | Monoclonal antibodies | |
| EP0265847A3 (en) | Monoclonal antibody | |
| GB8610202D0 (en) | Monoclonal antibodies | |
| GB8610203D0 (en) | Monoclonal antibodies | |
| GB8416845D0 (en) | Monoclonal antibodies | |
| GB8419456D0 (en) | Monoclonal antibodies | |
| ZA856374B (en) | Immunoassay for breast cancer employing monoclonal antibodies | |
| GB8619905D0 (en) | Monoclonal antibody | |
| NO882162L (no) | Monoklonale antistoffer mot ovariekreftceller (ovb-3). | |
| GB8432502D0 (en) | Monoclonal antibody | |
| GB8421944D0 (en) | Monoclonal antibodies |